• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

PD-325901

Product ID P1202
Cas No. 391210-10-9
Purity ≥99%
Product Unit SizeCostQuantityStock
5 mg $131.90 In stock
25 mg $485.10 In stock
100 mg $1,008.80 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

PD-325901 is an anticancer chemotherapeutic MEK1/2 and Raf inhibitor that is particularly effective against cancers harboring B-Raf or Ras mutations such as V600E. PD-325901 decreases levels of phosphorylated ERK1/2, cyclin D1, and thymidine kinase 1. PD-325901 also induces cell cycle arrest at the G0/G1 phase, inhibiting proliferation in thyroid cancer cell lines. In vivo, this compound decreases tumor growth and size. Additionally, PD-325901 displays antiviral benefit, synergizing with other treatments in cellular models of influenza infection.

Product Info

Cas No.

391210-10-9

Purity

≥99%

Formula

C16H14F3IN2O4

Formula Wt.

482.19

Chemical Name

N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

IUPAC Name

N-[(2R)-2,3-dihydroxypropoxy]-3, 4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

Synonym

PD0325901

Solubility

Soluble in DMSO at 12 mg/mL; soluble in ethanol at 6.3 mg/mL with slight warming; very poorly soluble in water

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

P1202 MSDS PDF

Info Sheet

P1202 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Haasbach E, Hartmayer C, Planz O. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res. 2013 May;98(2):319-24. PMID: 23523553.

Leyton J, Smith G, Lees M, et al. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther. 2008 Sep;7(9):3112-21. PMID: 18790789.

Liu D, Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid. 2008 Aug;18(8):853-64. PMID: 18651802.

Brown AP, Carlson TC, Loi CM, et al. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol. 2007 Apr;59(5):671-9. PMID: 16944149.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only